Search compounds with antimicrobial activity by applying molecular topology to selected quinolones

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 16, 2003, Pages 2699-2702

  Mut Ronda, S ^a   Salabert Salvador, M T ^a   Duart, M J ^b   Anton Fos G M ^b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSIDAD CEU CARDENAL HERRERA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1 ETHYL 7 [3 (ETHYLAMINOMETHYL) 1 PYRROLIDINYL] 6,8 DIFLUORO 1,4 DIHYDRO 4 OXO 3 QUINOLINECARBOXYLIC ACID; 6 FLUORO 1 METHYL 4 OXO 7 (1 PIPERAZINYL) 4H 1,3 THIAZETO[3,2 A]QUINOLINE 3 CARBOXYLIC ACID; AMIFLOXACIN; BALOFLOXACIN; BAYY 3118; CINOXACIN; CIPROFLOXACIN; CLINAFLOXACIN; DICLOFENSINE; DIFLOXACIN; E 3604; ENOXACIN; FLEROXACIN; FLUMEQUINE; LOMEFLOXACIN; MEFLOQUINE; MILOXACIN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; OXOLINIC ACID; PAMAQUINE; PAPAVEROLINE; PEFLOXACIN; PENTAQUINE; PIPEMIDIC ACID; PIPEQUALINE; QUINOLINE; QUINOLINE DERIVATIVE; REBAMIPIDE; RO 149578; ROSOXACIN; RUFLOXACIN; TEMAFLOXACIN; TERAZOSIN; UNINDEXED DRUG;

ANTIMICROBIAL ACTIVITY; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; ENTEROBACTER AEROGENES; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; LINEAR REGRESSION ANALYSIS; MOLECULAR DYNAMICS; NONHUMAN; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STAPHYLOCOCCUS AUREUS; THEORETICAL STUDY;

EID: 0037811325     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00544-4     Document Type: Article

References (22)

1. Kier L.B., Hall L.H. J. Pharm. Sci. 65:1976;1806.
2. Podlogar B.L., Ferguson D.M. Drug Des. Discov. 17:2000;4.
3. Olson G. Drug Des. Discov. 17:2001;191.
4. Balaban A.T. MATCH (Commun. Math. Chem.). 21:1986;115.
5. Balaban A.T. Pure Appl. Chem. 55:1983;199.
6. Kier L.B., Murray W.J., Randic M., Hall L.H. J. Pharm. Sci. 65:1976;1226.
7. Kier, L. B.; Hall, L. H. Molecular Connectivity in Structure-Activity Analysis; Research Studies: Letchworth, 1986.
8. Balaban A.T. Chem. Phys. Lett. 89:1982;399.
9. Lien E.J. S.A.R. Side Effects and Drug Design. 1987;Marcel Dekker, New York.
10. Duart M.J., García-Domenech R., Antón-Fos G.M., Gálvez J. J. Comput. Aid. Mol. Des. 15:2001;561.
11. Andriole V.T. Las Quinolonas. 1989;Academic, San Diego.
12. Karki R.G., Kulkami V.M. Bioorg. Med. Chem. 9:2001;3153.
13. Strom M.B., Harg B.E., Rekdel O., Skar M.L., Stensen W., Svendsen J.J. Biocehm. Cell. Biol. 80:2002;65.
14. Dixon, W. J.; Brown, M. B.; Engelman, L.; Jennrich, R. I. BMDP Statistical Software Manual; University of California; Berkeley, CA, 1990, Vol. I, p 339.
15. Gootz, T. D.; Brighty, K. E., In Quinolones; Andriole, V. T., Ed.; Academic: San Diego, 1998; p 29.
16. Gobernado M., Santos M. Medicine. 67:1988;33.
17. Dalhoff, A.; Bergan, T. Pharmacokinetics of Fluoroquinolones in Experimental Animals. In Quinolones Antibacterials; Kuhlmann, J., Dalhoff, A., Zeiler, H. J., Eds.; Springer: Berlin, 1998; p 179.
18. Fukuda H., Hori S., Hiramatsu K. Antimicrob. Ag. Chemother. 42:1998;1917.
19. Neu H.C. Am. J. Med. 87:1989;6C-2S.
20. Ozaki M., Tomii Y., Matsuda M., Segawa J., Kitano M., Kise M., Nishino T. Chemotheraphy. 44:1998;21.
21. Kamenska V., Mekenyan O., Sterev A., Nedjalkova Z. Arzneimittelforschung. 46:1996;423.
22. Martin S.J., Meyer J.M., Chuck S.K., Jung R., Messick C.R., Pendland S.L. Ann. Pharmacother. 32:1998;320.